title: Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient.
abstract: The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m(2) on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.
authors.affiliation: Oncohematology Unit, University of Perugia, S Maria Hospital, Terni, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Gubbiotti
authors.affiliation: Oncology Unit, Macerata Hospital, Macerata, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pistilli
authors.affiliation: Medical Oncology Unit, San Salvatore Hospital, University of l'Aquila, L'Aquila, Italy.
authors.forename: Marianna
authors.initials: M
authors.lastname: Tudini
authors.affiliation: Oncology Unit, Macerata Hospital, Macerata, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Benedetti
authors.affiliation: Medical Oncology Unit, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Eva
authors.initials: E
authors.lastname: Galizia
authors.affiliation: Oncology Unit, Macerata Hospital, Macerata, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Rusiello
authors.affiliation: Oncology Unit, Macerata Hospital, Macerata, Italy.
authors.forename: Luciano
authors.initials: L
authors.lastname: Latini
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005663:Furans / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D019572:Retinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D019233:Retreatment; D016896:Treatment Outcome; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
keywords: brain metastases; breast cancer; eribulin; retinal metastases